Advertisement

Topics

Constance Marie Company Profile

14:41 EST 21st November 2017 | BioPortfolio


News Articles [73 Associated News Articles listed on BioPortfolio]

stimOS: Constance-based Start-Up Company gains HTGF and MBG as investors

German HTGF acts as seed investor at stimOS GmbH located in Constance: Together with MBG, Baden-Württemberg (MBG), the seed stage investor provides 720,000 euros for further development and approval ...

Marie Curie: Iconic Scientist, Nobel Prize Winner...War Hero?

Ask people to name the most famous historical woman of science and their answer will likely be: Madame Marie Curie. Push further and ask what she did, and they might say it was something related to ra...

Author Marie Florence’s Newly Released “Ree’s Chronicles: The Price I Paid For A Cup Of Sugar” A Gripping Story Of Tragic Life Events And Learning To Surrender To God

(PRWEB) September 07, 2017 “Ree’s Chronicles: The Price I Paid for a Cup of Sugar”: a captivating and inspiring story...

Acceleron starts Phase II trial of ACE-083 to treat Charcot-Marie-Tooth disease

Dr. Marie-Paule Kieny Appointed To The Human Vaccines Project Board Of Directors

  Life Sciences Jobs   ...

Acceleron Pharma Announces First Patient Treated In Phase II Clinical Trial Of ACE-083 In Charcot-Marie-Tooth Disease

  Life Sciences Jobs   ...

PHARNEXT Amends The Protocol Of The International Pivotal Phase III Trials Of PXT3003 For Charcot-Marie-Tooth Disease Type 1A

  Life Sciences Jobs   ...

PHARNEXT Announces That The Recommends Continuing The Ongoing Phase III Trial Of PXT3003 For Charcot-Marie-Tooth Disease Type 1A

  Life Sciences Jobs   ...

PubMed Articles [44 Associated PubMed Articles listed on BioPortfolio]

Charcot-Marie-Tooth Disease Type 1A: Influence of Body Mass Index on Nerve Conduction Studies and on the Charcot-Marie-Tooth Examination Score.

Charcot-Marie-Tooth Disease type 1A (CMT1A) is caused by a duplication of the peripheral myelin protein gene 22 at chromosome 17p11.2-12. There is limited data regarding whether body mass index (BMI) ...

Natural history of Charcot-Marie-Tooth disease during childhood.

To determine the rate of disease progression in a longitudinal natural history study of children with Charcot-Marie-Tooth disease (CMT).

Genetic and clinical characteristics of NEFL-related Charcot-Marie-Tooth disease.

To analyse and describe the clinical and genetic spectrum of Charcot-Marie-Tooth disease (CMT) caused by mutations in the neurofilament light polypeptide gene (NEFL).

Charcot-Marie-Tooth Disease and Other Genetic Polyneuropathies.

Genetic polyneuropathies are rare and clinically heterogeneous. This article provides an overview of the clinical features, neurologic and electrodiagnostic findings, and management strategies for Cha...

Different nerve ultrasound patterns in Charcot-Marie-Tooth types and HNPP.

Nerve ultrasound in Charcot-Marie-Tooth disease (CMT) has mostly focused on upper limbs. We performed an evaluation of a large cohort of CMT patients in which we sonographically characterized nerve ab...

Clinical Trials [18 Associated Clinical Trials listed on BioPortfolio]

Charcot-Marie-Tooth Disease (CMT) Infant Scale (INC-6611)

The purpose of this study is to develop and validate a clinical outcome measure to evaluate disability and disease progression of children 3 years of age and younger (infants and toddlers)...

Effects of Coenzyme Q10 on Charcot-Marie-Tooth Disease

The object of this research is to test the effectiveness of Coenzyme Q10 (CoQ10) on symptoms of weakness, fatigue, and pain in persons with Charcot-Marie-Tooth disease (CMT).In this study ...

Follow up and Observation of Charcot Marie Tooth Disease in Families

The study is aimed to test the hypothesis that there is anticipation in CMT

Study of ACE-083 in Patients With Charcot-Marie-Tooth Disease

This is a multicenter, phase 2 study to evaluate the safety, tolerability, pharmacodynamics (PD), efficacy, and pharmacokinetics (PK) of ACE-083 in patients with CMT1 and CMTX, to be condu...

Assessing Long Term Safety and Tolerability of PXT3003 in Patients With Charcot-Marie-Tooth Disease Type 1A

All randomised patients with Charcot-Marie-Tooth Type 1A (CMT1A) who completed the primary study CLN-PXT3003-02, i.e. 15-month double-blind treatment with PXT3003 or placebo, will be eligi...

Companies [26 Associated Companies listed on BioPortfolio]

Constance Marie

Ella Marie Foundation

The Ella Marie Foundation was founded in 1998 with a simple desire of helping others. Over the past 16 years, that mission has expanded into a cohesive effort to enhance the lives...

Constance Therapeutics

Constance Therapeutics is a vertically integrated medicinal cannabis company producing standardized and science-based whole plant cannabis extracts. The company has created a new ...

GATC Biotech AG .

GATC Biotech, with headquarters in Constance, Germany, at the beautiful Lake Constance, is a leading provider of molecular biological services & innovative bioinformatics solutions for industry & acad...

Marie Claire

More Information about "Constance Marie" on BioPortfolio

We have published hundreds of Constance Marie news stories on BioPortfolio along with dozens of Constance Marie Clinical Trials and PubMed Articles about Constance Marie for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Constance Marie Companies in our database. You can also find out about relevant Constance Marie Drugs and Medications on this site too.

Quick Search
Advertisement
 

Corporate Database Quicklinks



Searches Linking to this Company Record